Biofrontera Bioscience GMBH

Biofrontera Bioscience GmbH is a German pharmaceutical company based in Leverkusen, Germany, and is a wholly owned subsidiary of Biofrontera AG. Biofrontera AG, the parent company, was founded in 1997 and is publicly traded on the Frankfurt Stock Exchange (Prime Standard). As of December 31, 2025, Biofrontera AG reported an annual revenue of $41.7 million and employed 90 individuals as of March 31, 2026.

The company specializes in the development and commercialization of dermatological drugs and medical cosmetics for treating skin diseases. Key products include Ameluz®, a topical prescription drug used in photodynamic therapy (PDT) for certain superficial skin cancers and their precursors, such as actinic keratosis and superficial basal cell carcinoma. Biofrontera also markets the BF-RhodoLED® and BF-RhodoLED® XL red-light lamps, which are used in combination with Ameluz® for PDT. Biofrontera Bioscience GmbH specifically manages regulatory affairs, research and development, intellectual property, and medical affairs for the Biofrontera Group, holding patents and approvals for products like Ameluz® and BF-RhodoLED®.

Biofrontera Bioscience GmbH's patent litigation posture is defensive, as indicated by its record of zero cases as a plaintiff and one case as a defendant. The sole tracked case, Sun Pharmaceutical Industries Inc. v. Biofrontera Bioscience GmbH, is a proceeding at the Patent Trial and Appeal Board (PTAB), where Biofrontera Bioscience GmbH is acting as the defendant. This aligns with its role in holding the group's intellectual property.

The PTAB case initiated by Sun Pharmaceutical Industries Inc. against Biofrontera Bioscience GmbH, filed on January 16, 2026, involves photodynamic therapy systems and pharmaceutical products. This proceeding underscores the company's active involvement in protecting its proprietary dermatological treatments and related medical devices. Sun Pharmaceutical Industries Inc. is also recognized as a competitor to Biofrontera.